Baxter Buys Late-Stage Haemophilia Drug OBI-1 from Ipsen and Troubled Inspiration Biopharmaceuticals
By Heather Cartwright
Pharma Deals Review: Vol 2013 Issue 2 (Table of Contents)
Published: 2 Feb-2013
DOI: 10.3833/pdr.v2013.i2.1891 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Baxter has come to the rescue of Ipsen and its partner Inspiration Biopharmaceuticals, which filed for Chapter 11 bankruptcy protection in October 2012, by agreeing to acquire the companies’ lead haemophilia programme OBI-1, a recombinant porcine factor VIII (rpFVIII) in development for congenital haemophilia A with inhibitors and acquired haemophilia A...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS